The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes. The total trial duration per subject is approximately 58 weeks.
Inclusion Criteria:
Exclusion Criteria:
Metarie, Louisiana 70006, United States
Caba, C1118AAT, Argentina
Caba, C1440AAD, Argentina
Capital Federal, 1405, Argentina
Pohlheim, 35415, Germany
Saint Ingbert, 66386, Germany
Edgbaston, Birmingham, B15 2TH, United Kingdom